Literature DB >> 15895718

Genotype and phenotype in Fabry disease: analysis of the Fabry Outcome Survey.

E Schaefer1, A Mehta, A Gal.   

Abstract

AIM: Mutations of the gene (GLA) encoding alpha-galactosidase A are implicated in Fabry disease, a progressive, X-chromosomal inherited lysosomal storage disorder. FOS--the Fabry Outcome Survey - was established as a long-term surveillance study to describe the natural course of Fabry disease and its response to enzyme replacement therapy in a large cohort of European patients. Clinical phenotype, age of onset and course of Fabry disease are very variable, even within the same family, which makes it difficult to define a genotype-phenotype relationship by analysing individual patients. The FOS database contains detailed medical information on a large cohort of patients and thus has the potential to provide important information to address this question.
METHODS: At the time of analysis, information on 545 patients belonging to 157 families from nine European countries had been entered into the FOS database. A GLA mutation has been reported in 365 individuals (65% and 68% of all males and females, respectively) in FOS. These data were used to analyse the relationship between genotype and phenotype in Fabry disease.
RESULTS: A highly significant positive correlation was found between the age at entry into FOS and the FOS Severity Index in male patients with GLA missense mutations (p < 0.001) as well as in those carrying other types of mutations (p < 0.001). A positive correlation was also found between the age at entry into FOS and the number of affected organs in male patients with missense mutations, irrespective of whether the change in the amino acid side chain predicted in the alpha-galactosidase A protein was classified as a conservative or non-conservative change.
CONCLUSION: The data presented here suggest that there is a correlation between genotype and clinical severity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15895718     DOI: 10.1111/j.1651-2227.2005.tb02119.x

Source DB:  PubMed          Journal:  Acta Paediatr Suppl        ISSN: 0803-5326


  18 in total

1.  Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey.

Authors:  Andrea Sodi; Alexander S Ioannidis; Atul Mehta; Clare Davey; Michael Beck; Suzanne Pitz
Journal:  Br J Ophthalmol       Date:  2006-09-14       Impact factor: 4.638

2.  Rare diseases in Croatia--lesson learned from Anderson-Fabry disease.

Authors:  Mirando Mrsić; Marin Nola
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

Review 3.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

4.  Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha.

Authors:  Akemi Tanaka; Taisuke Takeda; Takao Hoshina; Kazuyoshi Fukai; Tsunekazu Yamano
Journal:  J Inherit Metab Dis       Date:  2010-06-22       Impact factor: 4.982

Review 5.  Infrared imaging microscopy of bone: illustrations from a mouse model of Fabry disease.

Authors:  Adele L Boskey; Michel Goldberg; Ashok Kulkarni; Santiago Gomez
Journal:  Biochim Biophys Acta       Date:  2006-03-15

6.  Functional studies of new GLA gene mutations leading to conformational Fabry disease.

Authors:  C Filoni; A Caciotti; L Carraresi; C Cavicchi; R Parini; D Antuzzi; A Zampetti; S Feriozzi; P Poisetti; S C Garman; R Guerrini; E Zammarchi; M A Donati; A Morrone
Journal:  Biochim Biophys Acta       Date:  2009-11-24

7.  Mutant alpha-galactosidase A enzymes identified in Fabry disease patients with residual enzyme activity: biochemical characterization and restoration of normal intracellular processing by 1-deoxygalactonojirimycin.

Authors:  Satoshi Ishii; Hui-Hwa Chang; Kunito Kawasaki; Kayo Yasuda; Hui-Li Wu; Scott C Garman; Jian-Qiang Fan
Journal:  Biochem J       Date:  2007-09-01       Impact factor: 3.857

Review 8.  Fabry's disease: an example of cardiorenal syndrome type 5.

Authors:  Aashish Sharma; Marco Sartori; Jose J Zaragoza; Gianluca Villa; Renhua Lu; Elena Faggiana; Alessandra Brocca; Luca Di Lullo; Sandro Feriozzi; Claudio Ronco
Journal:  Heart Fail Rev       Date:  2015-11       Impact factor: 4.214

9.  Prediction of the responsiveness to pharmacological chaperones: lysosomal human alpha-galactosidase, a case of study.

Authors:  Giuseppina Andreotti; Mario R Guarracino; Marco Cammisa; Antonella Correra; Maria Vittoria Cubellis
Journal:  Orphanet J Rare Dis       Date:  2010-12-07       Impact factor: 4.123

Review 10.  Fabry disease.

Authors:  Dominique P Germain
Journal:  Orphanet J Rare Dis       Date:  2010-11-22       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.